文献速递消化道肿瘤与早癌消化内镜消化道出血

早期胃癌内镜黏膜下剥离术围手术期抗血小板药物管理与术后出血风险的关联:一项全国多中心研究分析

Association between perioperative management of antiplatelet agents and risk of post-endoscopic submucosal dissection bleeding in early gastric cancer: analysis of a nationwide multicenter study.
PubMed 文献 · Gastrointest Endosc · 2023-01-11

该研究基于日本33家机构2013年11月至2016年10月接受内镜黏膜下剥离术的早期胃癌患者数据,回顾性分析抗血小板药物状态与术后出血的关系。共纳入9736例,阿司匹林持续用药组与术后出血显著相关(OR 2.79,95%CI 1.77-4.37),噻吩吡啶类替换为阿司匹林或西洛他唑与术后出血无显著关联(OR 1.85,95%CI 0.72-4.78),西洛他唑单药治疗无论用药状态均无显著关联。

要点

  • 阿司匹林持续用药与早期胃癌内镜黏膜下剥离术后出血显著相关(OR 2.79)。
  • 噻吩吡啶类替换为阿司匹林或西洛他唑与术后出血无显著关联(OR 1.85)。
  • 西洛他唑单药治疗者无论用药状态与术后出血均无显著关联。

核心结论

  • 对于早期胃癌患者,将噻吩吡啶类替换为阿司匹林或西洛他唑可能可接受,以同时最小化内镜黏膜下剥离术后出血和血栓栓塞风险。
  • 对于接受内镜黏膜下剥离术的西洛他唑单药治疗患者,继续治疗可能可接受。

研究设计与样本

  • 本研究为对日本近期开展的一项全国多中心研究的二次分析。
  • 回顾性纳入2013年11月至2016年10月期间在33家机构接受内镜黏膜下剥离术的早期胃癌患者,患者使用抗血小板药物或未接受抗血栓治疗。
  • 主要结局为内镜黏膜下剥离术后出血率与每种抗血小板药物状态的关系。
  • 共9736例患者纳入分析。

主要发现

  • 在665例阿司匹林使用者中,持续用药组与术后出血显著相关(OR 2.79;95%CI 1.77-4.37)。
  • 在227例噻吩吡啶类使用者中,替换为阿司匹林或西洛他唑组与术后出血无显著关联(OR 1.85;95%CI 0.72-4.78)。
  • 在158例西洛他唑使用者中,无论用药状态如何,与术后出血均无显著关联。
  • 在双联抗血小板治疗使用者中,无论抗血小板药物给药状态如何,术后出血率约为10%至20%。
  • 本研究中无患者发生血栓栓塞事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Data are lacking regarding post-endoscopic submucosal dissection (ESD) bleeding in patients with early gastric cancer (EGC) who take antiplatelet agents (APAs), particularly in those taking thienopyridine and cilostazol. We aimed to clarify the association between the status of APA medication and post-ESD bleeding risk. METHODS: This study is a secondary analysis using data from a recently conducted nationwide multicenter study in Japan. We retrospectively reviewed patients treated with APAs or on no antithrombotic therapy recruited from 33 institutions who underwent ESD for EGC between November 2013 and October 2016. The primary outcome of this study was the relationship between the rate of post-ESD bleeding and the status of each APA medication. RESULTS: A total of 9736 patients were included in the analysis. Among 665 aspirin users, the continuation group was significantly associated with post-ESD bleeding (odds ratio [OR], 2.79; 95% confidence interval [CI], 1.77-4.37). Among 227 thienopyridine users, the aspirin or cilostazol replacement group was not significantly associated with post-ESD bleeding (OR, 1.85; 95% CI, .72-4.78). Among 158 cilostazol users, there was no significant association with post-ESD bleeding, irrespective of medication status. The rate of post-ESD bleeding was approximately 10% to 20% irrespective of the status of APA administration among dual-antiplatelet therapy users. No patients experienced thromboembolic events in this study. CONCLUSIONS: Replacement of thienopyridine with aspirin or cilostazol may be acceptable for minimizing both the risk of post-ESD bleeding and thromboembolism in patients with EGC. In patients on cilostazol monotherapy undergoing ESD, continuation of therapy may be acceptable.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Miura Y, Tsuji Y, Yoshio T, et al. Association between perioperative management of antiplatelet agents and risk of post-endoscopic submucosal dissection bleeding in early gastric cancer: analysis of a nationwide multicenter study. Gastrointest Endosc. 2023. PMID: 36639059. doi:10.1016/j.gie.2022.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。